Nanomedicine News RSS Feed - Nanomedicine

Novel Microfluidic Chip Can Capture Rare Clusters of Circulating Tumor Cells

Novel Microfluidic Chip Can Capture Rare Clusters of Circulating Tumor Cells

Researchers have developed a microfluidic chip that can capture rare clusters of circulating tumor cells, which could yield important new insights into how cancer spreads. The work was funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health. [More]
Toxin-Absorbing Nanosponges in Gels Could Help Treat MRSA Infections

Toxin-Absorbing Nanosponges in Gels Could Help Treat MRSA Infections

Nanoengineers at the University of California, San Diego developed a gel filled with toxin-absorbing nanosponges that could lead to an effective treatment for skin and wound infections caused by MRSA (methicillin-resistant Staphylococcus aureus), an antibiotic-resistant bacteria. This "nanosponge-hydrogel" minimized the growth of skin lesions on mice infected with MRSA - without the use of antibiotics. The researchers recently published their findings online in Advanced Materials. [More]
NantPharma to Acquire Rights to Cynviloq Through Acquisition of Igdrasol

NantPharma to Acquire Rights to Cynviloq Through Acquisition of Igdrasol

Sorrento Therapeutics, Inc., announced today that NantPharma, founded by Dr. Patrick Soon-Shiong and a member of the NantWorks ecosystem of companies, agreed to acquire the rights to Cynviloq through the acquisition of Igdrasol, Inc., a wholly-owned subsidiary of Sorrento, which has been developing Cynviloq (paclitaxel nanoparticle polymeric micelle) in a bio-equivalence trial. [More]
CCC Awards Grants to Test RNA Nanotherapy to Target MED1 in Breast Cancer Cells

CCC Awards Grants to Test RNA Nanotherapy to Target MED1 in Breast Cancer Cells

For the second year, the Cincinnati Cancer Center (CCC) has awarded $160,000 in pilot grants to members and basic scientists who are collaborating to find out more about various cancers with hopes of generating more data and additional funding. [More]
Celsion’s TheraSilence Technology Effectively Delivers miR-145 Inhibitor in Well-Established PAH Model

Celsion’s TheraSilence Technology Effectively Delivers miR-145 Inhibitor in Well-Established PAH Model

Celsion Corporation, a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today reported the publication of an abstract in the prestigious Journal of Controlled Release summarizing findings from a preclinical study confirming effective delivery of RNA to lung cells. [More]
Therapeutic Cells Encapsulated in Nanoporous Capsules Can Treat from Within Tumors

Therapeutic Cells Encapsulated in Nanoporous Capsules Can Treat from Within Tumors

Attacking the perennial problem of systemic toxicity from typical chemotherapy treatments, Dartmouth investigators, led by Barjor Gimi, PhD, have engineered therapeutic cells encapsulated in nanoporous capsules to secrete antitumor molecules from within the tumor. [More]
Dicerna Adds PNET Expansion Cohort to DCR-MYC Phase 1 Study in Solid Tumors, Multiple Myeloma or Lymphoma

Dicerna Adds PNET Expansion Cohort to DCR-MYC Phase 1 Study in Solid Tumors, Multiple Myeloma or Lymphoma

Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced it is expanding its ongoing Phase 1 study of DCR-MYC in solid tumors, multiple myeloma, or lymphoma to include a cohort of patients with pancreatic neuroendocrine tumors (PNETs) following early signs of clinical and metabolic response and tumor shrinkage in PNET patients. [More]
Phase Ib GEN-1 Trial for Platinum-Resistant Ovarian Cancer to be Presented at 2015 ASCO

Phase Ib GEN-1 Trial for Platinum-Resistant Ovarian Cancer to be Presented at 2015 ASCO

Celsion Corporation, a fully integrated oncology drug development company, today announced that results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented in poster session at the 2015 American Society of Clinical Oncology (ASCO) meeting in Chicago on Saturday, May 30th. GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein [More]
ASCO Annual Meeting 2015: Dicerna to Present New Data from DCR-MYC Phase 1 Study in Patients with Solid Tumors

ASCO Annual Meeting 2015: Dicerna to Present New Data from DCR-MYC Phase 1 Study in Patients with Solid Tumors

Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced that new clinical data from a Phase 1 study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2, 2015 in Chicago. [More]
Sanofi Exercises Option to Exclusive License to Develop Immunotherapy for Celiac Disease Treatment

Sanofi Exercises Option to Exclusive License to Develop Immunotherapy for Celiac Disease Treatment

Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. [More]
Site Sponsors
  • Strem Chemicals - Nanomaterials for R&D
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Park Systems - Manufacturer of a complete range of AFM solutions